Blood Testing Startup Sight Raises $28 Million

Blood testing startup S.D. Sight Diagnostics Ltd. raised $28 million by issuing private preferred stock, the company announced Sunday via shareholder Clal Biotechnology Industries Ltd. The company previously raised $25 million according to Crunchbase.

Founded in 2011, Israel-based Sight develops machine vision-based technology for blood test analysis and infectious disease diagnosis. Its malaria detection system Parasight is in use by healthcare providers in Asia, Africa, and Europe, and its blood count device OLO, which aims to deliver real-time lab-quality results without a lab, has received a CE Mark (European approval) and is currently in the process of being submitted for U.S. Food and Drug Administration approval.